Delivery Order SPE2DB24D9222-SPE2DB24FAZBL
Award Date 3/26/24
Potential Completion Date 4/16/24
Potential Value $12K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML SYRINGE. The contract, valued at $27,853.20, has an ultimate completion date of May 3, 2024. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB, held by DMS Pharmaceutical Group with DLA, valued at up to $4,999,999 through the end of 2025. The IDV enables DLA to issue...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract, number SPE2DB24FZB70, to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 MG/ML SYRINGEML. The $18,568.80 order has an ultimate completion date of April 16, 2024. This delivery order is part of a larger indefinite delivery contract, number SPE2DB22D9143, that DMS Pharmaceutical Group holds with DLA, valued at up to $4,999,999 through the end of 2025. The IDC enables DLA...
- The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide XOLAIR 150 MG/ML SYRINGEML for a potential value of $1,547.40. This order is part of a larger indefinite delivery vehicle contract, 4600082013 under the DLA's SPE2DB program, valued up to $4,999,999 through 2025. Through this contract, DMS Pharmaceutical Group supplies a broad range of pharmaceutical items to military health facilities...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Xolair 150 mg/mL syringes. The contract, valued at $9,284.40, has an ultimate completion date of April 23, 2024. This delivery order falls under DMS Pharmaceutical Group's existing indefinite delivery contract, SPE2DB22D9362, with the DLA worth up to $4,999,999 through the end of 2025. This larger contract enables the DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML SYRINGEML. The firm fixed-price contract has a potential value of $4,642.20 and a completion date of February 26, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, valued at up to $4,999,999 through 2025. The...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Xolair 150 mg/mL syringes. The award, valued at $7,737.00, is part of a larger single-award Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999 that runs through December 31, 2025. This IDC, under the DLA's SPE2DB program, allows the agency to issue delivery...
- The U.S. government agency, the Defense Logistics Agency (DLA), awarded a $11,605.50 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the provision of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with a completion date of February 25, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program....
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XOLAIR 150 MG/ML syringes and has a performance period through May 2, 2024. This award is placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with DLA, valued at up to $4,999,999 through 2025. Under this broader contract vehicle, DMS Pharmaceutical Group...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $4,642.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the supply of XOLAIR 150 MG/ML SYRINGE, a biologic medication, to support the recurring medical needs of military health facilities. The award is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to...